Mega-block­buster? Pfiz­er lines up for a snap re­view of its PARP drug ta­la­zoparib — and a launch in­to a crowd­ed mar­ket

Pfiz­er $PFE gets to cut in line at the FDA with its ap­pli­ca­tion for the PARP in­hibitor ta­la­zoparib, which is like­ly head­ed for a mar­ket show­down with a slate of ri­vals.

Bought out in the $14 bil­lion Medi­va­tion ac­qui­si­tion, Pfiz­er has steered ta­la­zoparib through a suc­cess­ful, though dis­tinct­ly un­spec­tac­u­lar, Phase III pro­gram for pa­tients with germline BR­CA-mu­tat­ed, HER2-neg­a­tive breast can­cer. And now the agency has of­fered Pfiz­er a pri­or­i­ty re­view, putting a de­ci­sion dead­line in De­cem­ber and giv­ing agency com­mis­sion­er Scott Got­tlieb an op­por­tu­ni­ty to fol­low through on his promise to add com­pet­ing drugs to the mar­ket­place in search of low­er prices.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER